Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remdesivir in Severe COVID-19
NCT04292899Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2020
- Primary completion
- Apr 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 15
01
Overview
A Phase 3 trial of remdesivir in coronavirus disease 2019 (COVID-19), sponsored by Gilead Sciences. Started Mar 2020; status: completed.
02
Drugs
remdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04292899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04292899.